Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing’s disease

Osilodrostat: First Approval

(2020) Sean Duggan   DRUGS

Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase

(2020) Rosario Pivonello et al.   Lancet Diabetes & Endocrinology

Cushing’s Disease

(2019) Nishioka et al.   Journal of Clinical Medicine

DIAGNOSIS OF ENDOCRINE DISEASE: The role of the desmopressin test in the diagnosis and follow-up of Cushing’s syndrome

(2018) Dimitra Argyro Vassiliadi et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Advances in the medical treatment of Cushing's syndrome

(2018) Richard A Feelders et al.   Lancet Diabetes & Endocrinology

The Treatment of Cushing's Disease

(2015) Rosario Pivonello et al.   ENDOCRINE REVIEWS

Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline

(2015) Lynnette K. Nieman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cushing's syndrome

(2015) André Lacroix et al.   LANCET

Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease

(2015) Maria Fleseriu et al.   Pituitary

Changes in Plasma ACTH Levels and Corticotroph Tumor Size in Patients With Cushing's Disease During Long-term Treatment With the Glucocorticoid Receptor Antagonist Mifepristone

(2014) Maria Fleseriu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center

(2012) Camille Baudry et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

The 4mg Intravenous Dexamethasone Suppression Test in the Diagnosis of Cushing’s Syndrome

(2009) Caroline Jung et al.   CLINICAL ENDOCRINOLOGY

Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease

(2008) F Castinetti et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY